Cyndi Lauper showcases backstage psoriasis woes in Novartis' new Cosentyx spot

Cyndi Lauper Cosentyx
Real-life psoriasis sufferer Lauper teamed up with Novartis on a psoriasis-awareness push in 2015.

Cyndi Lauper is back to star in another round of Novartis’ psoriasis marketing.

The '80s pop music icon, who in 2015 partnered with the Swiss pharma giant and the National Psoriasis Foundation on a disease-awareness push, appears with two other real-life patients in Novartis’ latest Cosentyx spot.

RELATED: Novartis goes '80s with Cyndi Lauper-led psoriasis campaign

“It was tough getting out there on stage,” she narrates, as the camera shows her in her dressing room, trying to disguise her psoriasis with spray makeup—and failing. The commercial weaves Lauper’s story with those of two other patients, shown struggling with unwanted attention as people around them stare at the red, flaky skin patches caused by the disease.

But the video spot takes a triumphant turn after Lauper declares that “I found something that worked and keeps on working.”

“Never give up,” she urges viewers, adding, “clear skin can last” as she rocks out on stage and then walks into a crowd of adoring fans.

RELATED: Novartis bolsters its home-turf advantage in psoriasis with Cosentyx DTC push

The new work is part of Novartis’ “See Me” campaign, which the company launched last year to “play well with this patient base and further grow the brand,” as then-pharma chief David Epstein told investors on an early 2016 conference call.

The new spot comes in the face of some new competition. Since the Basel-based drugmaker rolled out its first DTC effort in psoriasis, Eli Lilly’s Taltz, Valeant’s Siliq and, most recently, Johnson & Johnson’s Tremfya have arrived on the next-gen psoriasis scene. Those rivals didn't stop Cosentyx from cracking the blockbuster barrier, though; it racked up $1.13 billion worldwide in 2016.

And as Johnson & Johnson execs recently reassured their own investors, there’s still plenty of market share to go around. “We believe it's only about 25% to 30% of the patients in that category [who] are actually on some of the newer agents,” CEO Alex Gorsky said. “So that in and of itself represents a significant opportunity.”